As on Wednesday, Spyre Therapeutics Inc (NASDAQ: SYRE) started slowly as it slid -5.39% to $15.96, before settling in for the price of $16.87 at the close. Taking a more long-term approach, SYRE posted a 52-week range of $10.91-$40.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 44.65%. Meanwhile, its Annual Earning per share during the time was 44.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 8.06%. This publicly-traded company’s shares outstanding now amounts to $60.74 million, simultaneously with a float of $51.32 million. The organization now has a market capitalization sitting at $964.00 million. At the time of writing, stock’s 50-day Moving Average stood at $16.25, while the 200-day Moving Average is $20.61.
Spyre Therapeutics Inc (SYRE) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Spyre Therapeutics Inc’s current insider ownership accounts for 14.97%, in contrast to 99.81% institutional ownership. According to the most recent insider trade that took place on Nov 06 ’24, this organization’s Director sold 6,700 shares at the rate of 36.76, making the entire transaction reach 246,313 in total value, affecting insider ownership by 27,360. Preceding that transaction, on Oct 25 ’24, Company’s Director sold 300 for 36.43, making the whole transaction’s value amount to 10,929. This particular insider is now the holder of 34,060 in total.
Spyre Therapeutics Inc (SYRE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.88 per share during the current fiscal year.
Spyre Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 8.06% and is forecasted to reach -3.32 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -2.92% through the next 5 years, which can be compared against the 44.65% growth it accomplished over the previous five years trading on the market.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Let’s observe the current performance indicators for Spyre Therapeutics Inc (SYRE). It’s Quick Ratio in the last reported quarter now stands at 6.49.
In the same vein, SYRE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.05, a figure that is expected to reach -0.78 in the next quarter, and analysts are predicting that it will be -3.32 at the market close of one year from today.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Through scrutinizing the latest numbers posted by the [Spyre Therapeutics Inc, SYRE], it can be observed that its last 5-days Average volume of 0.58 million was lower the volume of 0.63 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 23.12% While, its Average True Range was 42.86%.
Raw Stochastic average of Spyre Therapeutics Inc (SYRE) in the period of the previous 100 days is set at 58.79%, which indicates a major rise in contrast to 11.34% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.98 that was lower than 1.07 volatility it exhibited in the past 100-days period.
